To facilitate the usage of cell-based BMP9 gene therapy for bone tissue regeneration, we characterize the in vivo osteoconductive bone tissue and actions regeneration potential of three clinically-used scaffold components, type I collagen sponge, hydroxyapatite-tricalcium phosphate (HA-TCP) and demineralized bone tissue matrix (DBM), using BMP9-expressing C2C12 osteoblastic progenitor cells. of BMP9-transduced C2C12 cells forms ectopic … Continue reading To facilitate the usage of cell-based BMP9 gene therapy for bone tissue regeneration, we characterize the in vivo osteoconductive bone tissue and actions regeneration potential of three clinically-used scaffold components, type I collagen sponge, hydroxyapatite-tricalcium phosphate (HA-TCP) and demineralized bone tissue matrix (DBM), using BMP9-expressing C2C12 osteoblastic progenitor cells